IMAPS-ETI-AG
13.1.2020 13:43:06 CET | Business Wire | Press release
The first ETI (Exchange Traded Instrument) under the public offering issuance program of Liechtenstein's iMaps ETI plc starts trading on the MTF of the Vienna Stock Exchange today.
The Haack Performance ETI was launched for the asset manager PP Asset Management, which is licensed by the German BAFIN. The note tracks the performance of the Haack investment strategy, which achieved a performance of almost 20% in the past year. "I am pleased that we start trading with our Actively Managed Certificate (AMC) on the Vienna Stock Exchange. This means that investors who do not want to follow the investment recommendations themselves all the time now also have easy access via stock exchange trading via their own broker to invest in our benchmark-independent product," says Hans-Jürgen Haack, Senior Manager at PP Asset Management and mastermind of the Haack investment strategy.
"We are pleased that we can welcome our first customer to the stock exchange for a public offering solution. The demand for these innovative investment vehicles or ETIs - Exchange Traded Instruments under our public offering program is increasing steadily and we will shortly announce further listings," summarizes Andreas Woelfl, founder & chairman of iMaps Capital Markets Group, the arranger.
"Exchange Listed Instruments" ETIs for short, issued by the Liechtenstein iMaps ETI AG combine the best of many worlds, public offering like an UCITS fund, exchange-traded similar to an ETF, flexible like an alternative investment fund and based on collateralization to Intertrust as a trustee in favor of ETI investors, to avoid the credit risk of the issuer. The demand shows us that we have met the needs of many asset managers with this financial innovation," summarizes Günter Woinar, CEO of iMaps Capital Markets European operations.
About iMaps ETI plc
iMaps ETI AG is an issuer of derivative securities in the Principality of Liechtenstein with a main business focus on Actively Managed Certificates and Fund-Linked Notes to be issued as a public offer in the EU & UK as well as private placements in Switzerland, Singapore and Hong Kong . The issuer is the wholly owned subsidiary of iMaps Capital Markets. The iMaps Capital Markets Group focuses on providing asset managers with the platform for issuing investment vehicles - either as actively managed certificates or fund linked notes with listing and offering in Europe and other jurisdictions. ETIs represent an interesting, rapidly growing and cost-efficient alternative to funds and thanks to the approved prospectus from iMaps ETI plc, there is the possibility of offering them to the public throughout the EU & UK.
Disclaimer: The prospectus for the issuance programme of Exchange Traded Instruments in the form of derivative securities got approved by FMA Liechtenstein and can be downloaded free of charge from the website www.imaps-capital.com/etis
Language: |
English |
Company: |
iMAPS ETI AG
|
Phone: |
+1345 232 1382 |
ISIN: |
CH0505798592 |
View source version on businesswire.com: https://www.businesswire.com/news/home/20200113005478/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom